Neuralstem is a biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Our lead asset, NSI-189, is a new chemical entity in Phase 2 clinical development for major depressive disorder (MDD). Our transplantational stem cell asset, NSI-566, is a spinal cord-derived neural stem cell line being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). These product candidates are based on the company’s proprietary neural stem cell technology.
20271 Goldenrod Lane
Germantown, MD 20876
Biological Product (Except Diagnostic) Manufacturing (325414)
Biological Products, Except Diagnostic Substances (2836)